German Health Spending Shows More Rapid Growth

12 December 1994

Spending by the German health funds increased more rapidly in third-quarter 1994 and the gap between the rates of spending growth and income growth widened, according to Health Ministry figures.

Spending per fund member in western Germany rose 6.7% over the same, year-earlier period, compared with a rise of 2.4% in basic wage rates on which contributions are calculated. Spending per member in first-half 1994 rose 6.4%, while basic wage rates went up 2.5%.

The public-sector funds reported a surplus of 517 million Deutschemarks ($328.8 million) in the first nine months of this year, but the local health funds, the OK, and the industrial funds, the BK, closed the nine-month period with deficits of 56 million and 333 million marks respectively. In contrast, the supplementary health funds, the EK, posted a surplus of almost 770 million marks.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK





Today's issue

Company Spotlight